Tirzepatide
Mounjaro, Zepbound, LY3298176
A dual GLP-1 and GIP receptor agonist used for type 2 diabetes and obesity, enhancing insulin secretion, suppressing glucagon, and promoting weight loss.
Not Yet Recruiting
NA
NCT06790225
Glucose-dependent INsulinotropic Polypeptide: Effect on Bone Remodelling and Cell Activity (GINEBRA)
Esbjerg Hospital - University Hospital of Southern Denmark
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04537923
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NCT07096063
Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk
Brigham and Women's Hospital
OBSERVATIONAL
Updated Dec 15, 2025
Not Yet Recruiting
PHASE4
NCT07096908
Tirzepatide Use in People With Obesity and Type 1 Diabetes
Dasman Diabetes Institute
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05024032
A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE3
NCT06918405
Efficacy and Safety of Tirzepatide for Weight Management
Chittagong Medical College
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE4
NCT06191848
Subcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
University of Melbourne
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06143956
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT06485089
Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
University of Kansas Medical Center
OBSERVATIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT03882970
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT04660643
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Completed
NA
NCT05078255
The Separate and Combined Effects of Long-term GIP and GLP-1 Receptor Activation in Patients with Type 2 Diabetes
Asger Lund, MD
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06994338
Tirzepatide for Alcohol Use Disorder
University of Southern California
INTERVENTIONAL
Updated Dec 15, 2025
Completed
PHASE3
NCT05963022
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO)
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06727331
Study of Tirzepatide for Recovery and Alcohol Use Management
Brigham and Women's Hospital
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE2
NCT06037252
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
Eli Lilly and Company
INTERVENTIONAL
Updated Dec 15, 2025
Not Yet Recruiting
NA
NCT07244458
Dietary Peanuts and Nutrition-Related Outcomes
Ian J. Neeland, MD
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
NCT07188545
Using Secondary Data to Evaluate Sex-based Heterogeneity of GLP-1 Agonists and SGLT2 Inhibitors on Cardiovascular-Kidney-Metabolic Health (CKMH) Outcomes in Real-world Settings (DASH-CKMH)
Ohio State University
OBSERVATIONAL
Updated Dec 15, 2025
Recruiting
PHASE2
NCT06582875
Glucagon-Like Peptide-1 Receptor Agonist in ADPKD
University of Colorado, Denver
INTERVENTIONAL
Updated Dec 15, 2025
Active Not Recruiting
PHASE1
NCT06648031
Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic Participants
Lexaria Bioscience Corp.
INTERVENTIONAL
Updated Dec 15, 2025